格隆汇6月30日丨精优药业(00858.HK)宣布，截至2025年3月31日止年度，主要由制造分类（在中国经营）为集团贡献的来自持续经营业务的收益及毛利为约55,400,000港元（2024年：59,100,000港元）及21,900,000港元（2024年：28,800,000港元）。公司拥有人应占集团年度溢利约为222,600,000港元，相较去年亏损约162,900,000港元。扭亏为盈主要...
Source Link格隆汇6月30日丨精优药业(00858.HK)宣布，截至2025年3月31日止年度，主要由制造分类（在中国经营）为集团贡献的来自持续经营业务的收益及毛利为约55,400,000港元（2024年：59,100,000港元）及21,900,000港元（2024年：28,800,000港元）。公司拥有人应占集团年度溢利约为222,600,000港元，相较去年亏损约162,900,000港元。扭亏为盈主要...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.